Axsome Therapeutics Competitive Intelligence & Landscape

Founded in January 2012 by Dr. Herriot Tabuteau, who also serves as its Chief Executive Officer and Chairman of the board of directors, Axsome Therapeutics is committed to scientific advancement in neuroscience [axsome.com/about-axsome/management-team/]. The company’s headquarters are not explicitly stated on the provided homepage content, but it operates as a U.S. biopharmaceutical company [axsome.com/contact-us/].

Axsome Therapeutics has a portfolio that includes approved products and a pipeline of innovative treatments. Key products include Auvelity® (dextromethorphan-bupropion) and Sunosi® (solriamfetol) [axsome.com/axs-portfolio/products/]. The company's pipeline features promising candidates such as AXS-05, AXS-12, and AXS-14, which are being developed for various CNS conditions [axsome.com].

Axsome Therapeutics focuses on a range of conditions including depression, Alzheimer’s disease agitation, migraine, narcolepsy, excessive daytime sleepiness, and fibromyalgia [axsome.com]. The company also has an intellectual property portfolio providing protection extending through 2040 [axsome.com/about-axsome/intellectual-property/].

As a growing and entrepreneurial company, Axsome Therapeutics emphasizes a patient-focused and passionate team, working to deliver scientific breakthroughs. The company's value proposition is centered on identifying critical gaps in care and developing differentiated products with novel mechanisms of action to achieve meaningful advancements in patient outcomes [axsome.com/careers/current-opportunities/].

Regarding pricing, Axsome Therapeutics determines the Wholesale Acquisition Cost (WAC) for its marketed prescription drugs, including Auvelity®, Sunosi®, and Symbravo® [https://www.axsome.com/wp-content/uploads/2024/11/auvelity-colorado.pdf][https://www.axsome.com/wp-content/uploads/2025/06/symbravo-colorado.pdf][https://www.axsome.com/wp-content/uploads/2024/11/sunosi-colorado.pdf]. It's important to note that the WAC does not necessarily reflect the actual price paid by various purchasers, as it doesn't account for price concessions offered to insurers or providers, nor the out-of-pocket cost to patients, which can be influenced by patient cost-sharing and manufacturer copay assistance programs [https://www.axsome.com/wp-content/uploads/2024/11/auvelity-colorado.pdf][https://www.axsome.com/wp-content/uploads/2025/06/symbravo-colorado.pdf][https://www.axsome.com/wp-content/uploads/2024/11/sunosi-colorado.pdf].

While specific pricing plans or tiers for patients are not publicly detailed on their website beyond the WAC information, the company's approach indicates a standard pharmaceutical pricing model where the WAC is a baseline before various discounts and patient assistance programs are applied.

Axsome Therapeutics also adheres to state disclosure requirements, providing information that may affect marketing and sales activities [https://www.axsome.com/about-axsome/state-disclosures/].

In addition to its marketed products, Axsome Therapeutics maintains a pipeline of investigational therapies, including AXS-05, AXS-12, and AXS-14 [https://www.axsome.com/axs-portfolio/pipeline/]. AXS-05, for example, is a novel oral NMDA receptor antagonist being developed for CNS conditions, consisting of a proprietary formulation of dextromethorphan and bupropion [https://www.axsome.com/axs-portfolio/pipeline/about-axs-05/]. These pipeline assets represent potential future additions to their product offerings, which would then follow similar pricing considerations upon market approval.

Recent job postings indicate a strategic focus on Alzheimer's Disease Agitation, with a notable opening for an "Associate Director/Director, Long Term Care Marketing (Alzheimer's Disease Agitation)" [axsome.com/careers/current-opportunities/]. This suggests a concentrated effort to market and grow their products within this therapeutic area, such as their recently approved treatment for agitation associated with dementia due to Alzheimer’s disease [axsome.com/].

Axsome Therapeutics is actively recruiting for various roles, signaling a period of expansion rather than layoffs. Their careers page invites "excellent candidates who share a strong interest in our company's mission" to join their "creative, entrepreneurial, and growing" team [axsome.com/careers/]. This consistent pattern of seeking new talent underscores their commitment to advancing novel therapies for central nervous system (CNS) conditions, including depression, migraine, and fibromyalgia, among others [axsome.com/].

The company is actively engaged in developing a robust pipeline of innovative treatments, including AXS-05, AXS-12, and AXS-14 [https://axsome.com/]. These pipeline assets, targeting significant CNS conditions like depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia [https://axsome.com/], represent potential future growth drivers and indications of ongoing investment in research and development. The presence of a Chief Financial Officer, Nick Pizzie, CPA, MBA, who joined Axsome Therapeutics in May 2018 [https://www.axsome.com/about-axsome/management-team/], further indicates a structured approach to financial management and corporate governance.

Although no specific M&A activities are detailed in the provided information, the company's focus on a broad portfolio and novel mechanisms of action for therapeutic options [https://www.axsome.com/about-axsome/] suggests a strategy centered on internal development and intellectual property acquisition. The continuous news updates regarding clinical trials, such as the initiation of Phase 3 trials for Solriamfetol in children and adolescents with ADHD in July and June 2026, respectively [https://axsome.com/], demonstrate ongoing investment and strategic advancement of its product offerings, which will likely influence its financial performance and valuation over time.

Further demonstrating their engagement, Axsome Therapeutics also presented at the 2021 ASCP Annual Meeting from June 1-4, detailing sustained efficacy with long-term treatment of AXS-05 [https://www.axsome.com/wp-content/uploads/2024/11/ASCP_2021_COMET_overall_poster_FINAL.pdf]. In 2020, the company highlighted emerging science at the AAN Science Highlights with data on the efficacy and safety of AXS-07 for acute migraine treatment [https://www.axsome.com/wp-content/uploads/2024/11/Axsome_AXS-07-Presentation_AAN-Emerging-Science-2020.pdf]. These presentations often involve collaborative research with academic institutions and feature key personnel from Axsome Therapeutics.

Beyond scientific conferences, Axsome Therapeutics engages with the broader community through various channels. They maintain a presence on social media platforms like Twitter and LinkedIn, which serve as additional avenues for communication and event promotion [https://www.axsome.com/science/publications/]. The company's website also features dedicated sections for "News & Events" and "Webcasts & Presentations," indicating a commitment to sharing updates and information with investors and the public [https://www.axsome.com/contact-us/] [https://www.axsome.com/axs-portfolio/pipeline/]. Furthermore, Axsome Therapeutics offers medical information and details on educational programs related to its products and pipeline, allowing interested parties to receive updates directly [https://www.axsome.com/science/medical-information/].